Back Article

  • Agnello V, Abel G, Elfahal M. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor[J]. Proc Natl Acad Sci USA, 1999, 96(): 12766-12771. doi: 10.1073/pnas.96.22.12766

  • Akazawa D, Date T, Morikawa K. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection[J]. J Virol, 2007, 81(): 5036-5045. doi: 10.1128/JVI.01573-06

  • Andre P, Komurian-Pradel F, Deforges S. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles[J]. J Virol, 2002, 76(): 6919-6928. doi: 10.1128/JVI.76.14.6919-6928.2002

  • Barth H, Cerino R, Arcuri M. Scavenger receptor class B type Ⅰ and hepatitis C virus infection of primary tupaia hepatocytes[J]. J Virol, 2005, 79(): 5774-5785. doi: 10.1128/JVI.79.9.5774-5785.2005

  • Barth H, Liang T J, Baumert T F. Hepatitis C virus entry: molecular biology and clinical implications[J]. Hepatology, 2006, 44(): 527-535. doi: 10.1002/(ISSN)1527-3350

  • Barth H, Schäfer C, Adah M I. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate[J]. J. Biol. Chem., 2003, 278(): 41003-41012. doi: 10.1074/jbc.M302267200

  • Barth H, Schnober E K, Zhang F. Viral and cellular determinants of hepatitis C virus envelope-heparan sulfate interaction[J]. J Virol, 2006, 80(21): 10579-10590. doi: 10.1128/JVI.00941-06

  • Barth H, Schnober EK, Zhang F. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction[J]. J Virol, 2006, 80(): 10579-10590. doi: 10.1128/JVI.00941-06

  • Bartosch B, Bukh J, Meunier J C. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes[J]. Proc Natl Acad Sci USA, 2003, 100(): 14199-14204. doi: 10.1073/pnas.2335981100

  • Bartosch B, Dubuisson J, Cosset F L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes[J]. J Exp Med, 2003, 197(): 633-642. doi: 10.1084/jem.20021756

  • Bartosch B, Verney G, Dreux M. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies[J]. J Virol, 2005, 79(): 8217-8229. doi: 10.1128/JVI.79.13.8217-8229.2005

  • Bartosch B, Vitelli A, Granier C. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor[J]. J Biol Chem, 2003, 278(43): 41624-41630. doi: 10.1074/jbc.M305289200

  • Baumert TF, Ito S, Wong DT. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells[J]. J Virol, 1998, 72(): 3827-3836.

  • Blanchard E, Belouzard S, Goueslain L. Hepatitis C virus entry depends on clathrin-mediated endocytosis[J]. J Virol, 2006, 80(): 6964-6972. doi: 10.1128/JVI.00024-06

  • Bowen D G, Walker C M. Adaptive immune responses in acute and chronic hepatitis C virus infection[J]. Nature, 2005, 436(): 946-952. doi: 10.1038/nature04079

  • Boyd M R, Gustafson K R, McMahon J B. Discovery of cyanovirin-N, a novel human immuno-deficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential appli-cations to microbicide development[J]. Antimicrob Agents Chemother, 1997, 41(): 1521-1530.

  • Chisari F V. Unscrambling hepatitis C virus-host interactions[J]. Nature, 2005, 436(): 930-932. doi: 10.1038/nature04076

  • Dreux M, Pietschmann T, Granier C. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI[J]. J Biol Chem, 2006, 281(): 18285-18295. doi: 10.1074/jbc.M602706200

  • Evans M J, von Hahn T, Tscherne D M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry[J]. Nature, 2007, 446(): 801-805. doi: 10.1038/nature05654

  • Hangartner L, Zinkernagel R M, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum[J]. Nat Rev Immunol, 2006, 6(): 231-243. doi: 10.1038/nri1783

  • Helle F, Goffard A, Morel V. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein[J]. J Virol, 2007, 81(): 8101-8111. doi: 10.1128/JVI.00127-07

  • Helle F, Wychowski C, Vu-Dac N. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans[J]. J Biol Chem, 2006, 281(): 25177-25183. doi: 10.1074/jbc.M602431200

  • Hemler M E. Tetraspanin functions and associated microdomains[J]. Nat Rev Mol Cell Biol, 2005, 6(): 801-811. doi: 10.1038/nrm1736

  • Hsu M, Zhang J, Flint M. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles[J]. Proc Natl Acad Sci USA, 2003, 100(): 7271-7276. doi: 10.1073/pnas.0832180100

  • Kapadia S B, Barth H, Baumert T. Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B type Ⅰ[J]. J Virol, 2007, 81(): 374-383. doi: 10.1128/JVI.01134-06

  • Koutsoudakis G, Herrmann E, Kallis S. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells[J]. J Virol, 2007, 81(): 588-598. doi: 10.1128/JVI.01534-06

  • Koutsoudakis G, Kaul A, Steinmann E. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses[J]. J Virol, 2006, 80(): 5308-5320. doi: 10.1128/JVI.02460-05

  • Krieger M. Scavenger receptor class B type Ⅰ is a multiligand HDL receptor that influences diverse physiologic systems[J]. J Clin Invest, 2001, 108(): 793-797. doi: 10.1172/JCI14011

  • Kwong P D, Doyle M L, Casper D J. HIV-1 evades antibody-mediated neutralization through confor-mational masking of receptor-binding sites[J]. Nature, 2002, 420(): 678-682. doi: 10.1038/nature01188

  • Lavillette D, Morice Y, Germanidis G. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection[J]. J Virol, 2005, 79(): 6023-34. doi: 10.1128/JVI.79.10.6023-6034.2005

  • Lee E, Pavy M, Young N. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses[J]. Antiviral Res, 2006, 69(): 31-38. doi: 10.1016/j.antiviral.2005.08.006

  • Lindenbach B D, Evans M J, Syder A J. Complete replication of hepatitis C virus in cell culture[J]. Science, 2005, 309(): 623-626. doi: 10.1126/science.1114016

  • Lindenbach B D. Rice C M. 2001. Flaviviridae: the viruses and their replication. In: Fields Virology (Knipe D M, Howley, P M, Griffin D E, et al. ed. ), 4th ed, Baltimore, Lippincott Williams & Wilkins, p991-1041.

  • Logvinoff C, Major M E, Oldach D. Neutralizing antibody response during acute and chronic hepatitis C virus infection[J]. Proc Natl Acad Sci USA, 2004, 101(): 10149-10154. doi: 10.1073/pnas.0403519101

  • Marsh M, Helenius A. Virus entry: open sesame[J]. Cell, 2006, 124(): 729-740. doi: 10.1016/j.cell.2006.02.007

  • Molina S, Castet V, Fournier-Wirth C. The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus[J]. J Hepatol, 2007, 46(): 411-419. doi: 10.1016/j.jhep.2006.09.024

  • O'Keefe B R, Smee D F, Turpin J A. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin[J]. Antimicrob Agents Chemother, 2003, 47(): 2518-2525. doi: 10.1128/AAC.47.8.2518-2525.2003

  • Penin F, Dubuisson J, Rey F A. Structural biology of hepatitis C virus[J]. Hepatology, 2004, 39(): 5-19. doi: 10.1002/(ISSN)1527-3350

  • Pestka J M, Zeisel M B, Blaser E. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C[J]. Proc Natl Acad Sci USA, 2007, 104(): 6025-6030. doi: 10.1073/pnas.0607026104

  • Pileri P, Uematsu Y, Campagnoli S. Binding of hepatitis C virus to CD81[J]. Science, 1998, 282(): 938-941. doi: 10.1126/science.282.5390.938

  • Poveda E, Briz V, Soriano V. Enfuvirtide, the first fusion inhibitor to treat HIV infection[J]. AIDS Rev, 2005, 7(): 139-147.

  • Scarselli E, Ansuini H, Cerino R. The human scavenger receptor class B type Ⅰ is a novel candidate receptor for the hepatitis C virus[J]. EMBO J, 2002, 21(): 5017-5025. doi: 10.1093/emboj/cdf529

  • Shenoy S R, O'Keefe B R, Bolmstedt A J. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins[J]. J Pharmacol Exp Ther, 2001, 297(): 704-710.

  • Srivastava I K, Ulmer J B, Barnett S W. Role of neutralizing antibodies in protective immunity against HIV[J]. Hum Vaccin, 2005, 1(): 45-60. doi: 10.4161/hv.1.2.1764

  • Steinmann D, Barth H, Gissler B. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C[J]. J Virol, 2004, 78(): 9030-9040. doi: 10.1128/JVI.78.17.9030-9040.2004

  • Takaki A, Wiese M, Maertens G. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C[J]. Nat Med, 2000, 6(): 578-582. doi: 10.1038/75063

  • Thimme R, Oldach D, Chang K M. Determinants of viral clearance and persistence during acute hepatitis C virus infection[J]. J Exp Med, 2001, 194(): 1395-1406. doi: 10.1084/jem.194.10.1395

  • Tscherne D M, Jones C T, Evans M J. Time-and temperature-dependent activation of hepatitis C virus for low-pHtriggered entry[J]. J Virol, 2006, 80(): 1734-1741. doi: 10.1128/JVI.80.4.1734-1741.2006

  • Voisset C, Callens N, Blanchard E. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type Ⅰ[J]. J Biol Chem, 2005, 280(): 7793-7799. doi: 10.1074/jbc.M411600200

  • von Hahn T, Lindenbach BD, Boullier A. Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells[J]. Hepatology, 2006, 43(): 932-942. doi: 10.1002/(ISSN)1527-3350

  • von Hahn T, Yoon J C, Alter H. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo[J]. Gastroenterology, 2007, 132(): 667-678. doi: 10.1053/j.gastro.2006.12.008

  • Wakita T, Pietschmann T, Kato T. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome[J]. Nat Med, 2005, 11(): 791-796. doi: 10.1038/nm1268

  • Wellnitz S, Klumpp B, Barth H. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines[J]. J Virol, 2002, 76(): 1181-1193. doi: 10.1128/JVI.76.3.1181-1193.2002

  • Wunschmann S, Medh J D, Klinzmann D. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor[J]. J Virol, 2000, 74(): 10055-10062. doi: 10.1128/JVI.74.21.10055-10062.2000

  • Yamada E, Montoya M, Schuettler C G. Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets[J]. J Gen Virol, 2005, 86(): 2507-2512. doi: 10.1099/vir.0.81169-0

  • Zeisel M B, Barth H, Schuster C, et al. 2008. Hepatitis C Virus Entry: Molecular Mechanisms and Targets for Antiviral Therapy. Front Biosci, in press.

  • Zeisel M B, Fafi-Kremer S, Fofana I. Host Neutralizing Responses in Hepatitis C Virus Infection[J]. World J Gastroenterol, 2007, 13(): 4824-4830. doi: 10.3748/wjg.v13.i36.4824

  • Zeisel M B, Koutsoudakis G, Schnober E K. Scavenger receptor BI is a key host factor for Hepatitis C virus infection required for an entry step closely linked to CD81[J]. Hepatology, 2007, 46(6): 1722-1731. doi: 10.1002/hep.v46:6

  • Zhang J, Randall G, Higginbottom A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection[J]. J Virol, 2004, 78(): 1448-1455. doi: 10.1128/JVI.78.3.1448-1455.2004

  • Zhong J, Gastaminza P, Cheng G. Robust hepatitis C virus infection in vitro[J]. Proc Natl Acad Sci USA, 2005, 102(): 9294-9299. doi: 10.1073/pnas.0503596102